OKYO Pharma Ltd ADR (OKYO)

Short interest in OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) significantly increased by 223.4% to 135,370 shares as of July 31st. This represents approximately 0.6% of the company's shares outstanding and a days-to-cover ratio of 0.9 days. Despite mixed analyst sentiment with a consensus "Hold" rating, HC Wainwright maintains a "Buy" rating with a target of $5.00, while the stock currently trades near its 12-month low.

OKYO Pharma Limited has filed an Amendment No. 1 to its annual report (Form 20-F/A) for the fiscal year ended March 31, 2026. This amendment solely revises the exhibit table to include the company's Clawback Policy as Exhibit 97, which was previously omitted. No other disclosures in the original report have been modified or updated for subsequent events.

OKYO Pharma's Chief Scientific Officer, Rajkumar V. Patil, has disclosed his initial holdings of common stock and stock options. As of March 18, 2026, Patil holds 16,667 shares of common stock directly and multiple stock option awards with various exercise prices and expiration dates ranging from 2033 to 2035. This Form 3 filing indicates initial beneficial ownership rather than recent trading activity.

OKYO Pharma's Chief Scientific Officer, Raj Patil, recently purchased 3,363 additional ordinary shares of the company at $1.49 per share, increasing his total holdings to 20,030 shares. The clinical-stage biopharmaceutical company is preparing to start a global Phase 3 clinical trial in the second half of the year to evaluate urcosimod for neuropathic corneal pain.

OKYO Pharma announced that its Chief Scientific Officer, Raj Patil, PhD, increased his holdings by purchasing 3,363 ordinary shares, bringing his total to 20,030 shares. The clinical-stage biopharmaceutical company is developing therapies for neuropathic corneal pain and anterior segment eye diseases, with a global Phase 3 clinical trial planned for later this year.